Gene-Altered Mice Boost Studies of Cardiomyopathy: Enables Research Into Causes And Treatment Of Heart Failure

June 01, 1998

University of Chicago cardiologists have created the first transgenic mouse that closely reproduces the clinical, anatomical and pathological features of dilated cardiomyopathy, allowing scientists an unprecedented opportunity to study the early changes associated with this fairly common disorder and to develop and test new therapies.

The finding is reported in the June 1 issue of the Journal of Clinical Investigation.

"This is a big step toward better understanding and better treatments for a prevalent and very deadly disease," said cardiologist Jeffrey Leiden, M.D., Ph.D., Frederick H. Rawson Professor of Medicine and Pathology at the University of Chicago and director of the study.

Dilated cardiomyopathy is an important cause of congestive heart failure, which affects more than four million Americans. Congestive heart failure is the most common cause of hospitalization for patients over the age of 65 and a leading cause of death.

In dilated cardiomyopathy the heart muscle expands and weakens -- ballooning out like an over-stretched rubber band -- until it can no longer pump blood efficiently. Patients complain of overwhelming fatigue, shortness of breath and chest pains. Lack of adequate circulation, in turn, can damage the lungs, liver, and other body systems.

Although cardiomyopathy has been associated with many possible triggers, such as viral infections or alcohol abuse, the cause is usually unknown. Idiopathic (of unknown cause) dilated cardiomyopathy (IDC), affects an estimated 36 out of every 100,000 people. Recent studies have shown that as many as 40 percent of those patients have a family history of the disorder, suggesting a genetic predisposition to the disease.

Dilated cardiomyopathy, like all forms of heart failure, tends to be diagnosed late in the course of the disease and to progress rapidly. There is no cure. Up to 50 percent of patients die or require a heart transplant within five years of diagnosis.

"This disease has remained extremely frustrating for patients and physicians," said Leiden, "because there has not been major scientific or therapeutic progress for decades."

The lack of an animal model has severely limited physicians' ability to understand the causes and mechanism of this disease and to develop new, more effective treatments. Since patients are usually diagnosed with advanced disease, knowledge of the early stages of cardiomyopathy is particularly limited.

"Without sufficient understanding," said Leiden, "we can only treat the symptoms, not the underlying disorder."

Even the value of diet and exercise as therapy for heart failure remain unsettled.

By altering one mouse gene, however, the research team has created a very accurate animal model of the disease. They introduced a mutant form, active only in the heart, of a gene called CREB, which controls the activity of several other genes that regulate the growth and development of cardiac muscle.

The altered gene -- which blocks the normal affects of CREB -- is turned on only after the mice mature. The mice are normal at birth, but a few weeks later, mice with the altered gene develop a severe and progressive form of dilated cardiomyopathy that precisely mirrors the human disease.

In gene-altered mice, the heart muscle expands and loses pumping strength. This results in an accumulation of fluid in the lungs, liver and legs. Like patients with IDC, these mice die prematurely, from 20 to 35 weeks after birth (about one third the normal life span).

"The clinical behavior, the anatomical changes and the microscopic evidence at autopsy are identical to human cardiomyopathy," said Leiden. "The progress of the disease is remarkably similar to the way heart failure affects humans."

For example, all four chambers of the mouse heart dilate, just like the human disorder. The muscle loses the ability to squeeze out blood or to refill after contracting. Fluid backs up, causing congestion in the lungs, liver, legs and abdomen.

Under the microscope, the cardiac tissue from the mice is indistinguishable from human heart tissue, showing the standard markings of cardiomyopathy -- cellular drop out, the appearance of fibrous tissue between muscle cells, the odd intermingling of oversized and tiny muscle cells, and the appearance of empty spaces within remaining muscle cells. The mice even develop "nutmeg liver," a classic finding in human cardiomyopathy, caused by the back-up of blood flow through that organ.

Diagnostic images of affected mice, taken with ultrasound or cardiac catheterization, also are identical to human disease. In fact, the researchers, working with engineers from Hewlett Packard, have developed non-invasive ultrasound heart-imaging equipment sensitive enough to follow the course of the disease in mice. Although mouse hearts beat eight-to-ten times a second and are no bigger than an M&M candy (that's plain, not peanut) the new technology allows sequential monitoring of these mice with echocardiography.

This mouse model should "hasten scientific understanding for dilated cardiomyopathy and improve therapy for heart failure," suggest the researchers. It should allow controlled testing of the effects of exercise and diet and permit more rapid testing of new medications.

"We are particularly excited about the opportunity to learn about the early stages of the disease," said Leiden, "which should gives us valuable clues about the biochemistry of cardiomyopathy and possible suggest ways to intervene before the damage is done."

Although CREB mutations have not been detected in human IDC, the similarity of the mouse and human versions suggests that the cardiac genes that CREB controls, a pathway that has not yet been mapped out, may play a crucial role in the development of IDC.

This research was supported by a grant from the National Heart, Lung, and Blood Institute. Additional authors of the paper include Richard Fentzke, Claudia Korcarz, Roberto Lang and Hua Lin, all of the University of Chicago.

University of Chicago Medical Center

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to